Midazolam

Midazolam, marketed as Versed, occupies two sharply different but connected roles in the account: it is a medication familiar to intensive-care staff, and it is a substance later detected in patients who died during the crisis at Memorial Medical Center and other hospitals. Its presence became an important investigative clue, but not a self-interpreting answer. The distinction between a drug’s clinical use, its detection in a body, its role in causing death, and the intent behind its administration remained contested throughout the investigation.

Clinical Use and Context

At Memorial, nurse Karen Wynn recognized midazolam as part of a combination she was accustomed to giving to patients on ventilators. Along with morphine, it could sedate a patient and, when indicated, reduce the patient’s drive to breathe so that a ventilator could do that work. The same combination might be used to ease pain, discomfort, or air hunger before a breathing tube was removed after a decision to withdraw life support. In that setting, the medication was associated with comfort during an already-decided end-of-life process; its purpose and significance depended on the patient’s clinical circumstances and the care plan.

The conditions at the hospital complicated that familiar context. Many patients did not have intravenous lines. Wynn and Anna Pou requested boxes of IV catheters, but not the fluids and tubing that would have been needed to hydrate patients who were hot and unable to drink independently. A young nurse, who had previously been told by Kathleen Fournier not to start IVs in the DNR patients during emergency mode, found it unusual to see staff placing IVs in the still-living patients. She was directed to leave the area and pack her belongings. The episode placed the administration of medication alongside unresolved questions about what care was being provided, to whom, and for what immediate purpose.

Wynn believed that the patients were already dying and would probably die whether or not they received morphine and midazolam, though she thought the drugs could hasten the process. She also considered the physical demands and risks of moving patients through the hospital and up to the garage. When she treated an elderly woman who was struggling to breathe, Wynn later recalled diluting a 10-milligram vial of morphine with a small amount of midazolam in saline and administering it through an IV. The woman appeared less distressed and died about half an hour later. Wynn understood the medication as a means of providing comfort in circumstances where she believed survival was not possible; the timing of the death also made the medication relevant to later scrutiny.

From Medication to Investigative Evidence

The drug’s role changed as investigators examined the deaths. Therese Mendez recalled asking Pou what drugs were involved after Pou said a decision had been made to administer lethal doses. Mendez later could not remember the full list, though she recalled morphine and Ativan and said she was unsure about the rest. In Virginia Rider’s arrest-warrant affidavit, the account of the seventh-floor events included the allegation that Pou told Mendez patients would receive a lethal dose and that LifeCare staff should leave. The affidavit also said Steven Harris supplied Pou with morphine, Versed, and injection materials. These were allegations assembled from witness accounts and toxicology, not findings that the detection of midazolam alone could establish.

After the evacuation, investigators learned that 125 vials of 10-milligram morphine, as well as dozens of injectable Versed and Ativan vials, were missing from the LifeCare pharmacy. Other controlled drugs remained, leading the investigators to regard the missing stock as selective rather than evidence of a general burglary. The missing midazolam supplies formed part of the material context of the inquiry, but the inventory did not by itself establish who had taken or administered particular vials.

Postmortem testing gave investigators another kind of evidence. Because the bodies had remained in heat for more than a week, Orleans Parish coroner Frank Minyard initially doubted that autopsies could yield useful blood samples. A volunteer pathologist advised that drugs might remain detectable in more durable tissues, including liver, brain, and muscle, or in fluid collected in the abdomen. At the attorney general’s request, Minyard agreed to have a federal disaster mortuary team collect samples. On September 22, state and federal investigators brought tissue samples from eighteen Memorial bodies to National Medical Services, Inc., in Willow Grove, Pennsylvania.

Robert Middleberg, who directed the laboratory, reported that nine of the eighteen cases tested positive for morphine and that roughly another five or six tested positive for midazolam. He explained that midazolam is a benzodiazepine associated with settings such as operating suites and intubation, rather than a medication commonly prescribed for routine use at home. The laboratory also detected other familiar medicines, including antidepressants and drugs for gastric reflux. Middleberg considered the midazolam findings concerning and emphasized that the medical records would be important to interpreting them. He also cautioned that midazolam would not ordinarily be expected to accumulate through repeated use unless a patient was repeatedly undergoing procedures such as intubation and extubation or surgery.

Findings Across the Patient Cases

In a later review of forty-one bodies from Memorial and LifeCare, twenty-three tested positive for morphine, midazolam, or both. The investigators and experts did not treat those results as interchangeable with proof of a particular dose or cause of death. They asked whether a patient had received one large dose or repeated doses, whether kidney or liver problems could affect how drugs were processed, whether the combination would be hazardous for a patient not on a respirator, and whether the likely effects matched the known or estimated time of death.

The records of Alice Hutzler, a ninety-year-old LifeCare patient being treated for pneumonia, raised a specific question. Tests found morphine and midazolam in her liver, brain, and muscle tissue, although neither drug appeared in her chart as prescribed. The chart was current until a few hours before her death was recorded on September 1. It described her as resting comfortably on Wednesday afternoon, and her nurses had documented no complaints of pain or distress that night indicating a need for those drugs. Hutzler was one of nine seventh-floor LifeCare patients found with one or both drugs. All nine had been seen alive on the morning of September 1 and were listed as dead that afternoon.

The experts differed even when considering the same group of results. Cyril Wecht classified Hutzler’s death, and those of seven of the other eight seventh-floor patients, as homicides; he marked Elaine Nelson’s death as undetermined because her records indicated that she was close to death that morning. Michael Baden considered all nine deaths homicides. Those conclusions were expert assessments of the cases, not a claim that a positive midazolam test alone settled every question about administration or intent.

Limits and Disputes in Forensic Interpretation

The condition of the bodies made the toxicology difficult to interpret. Heat and decomposition might change drug concentrations after death, so a measurement from postmortem tissue could not be read as if it were a blood test from a living patient. Middleberg advised the review group to consider the laboratory results alongside each patient’s medical history. In practical terms, the test could establish that midazolam was present in sampled tissue, while questions about the concentration before death, the dose administered, the timing, and the drug’s contribution to death required additional evidence.

Minyard consulted Steven Karch, a toxicologist who argued that drug levels in a cadaver might not correspond to levels immediately before death. Karch concluded that after bodies had spent ten days in extreme heat, the medical cause of death should remain undetermined. Baden challenged the implication that uncertainty about exact dosage erased the significance of the findings: he stressed that morphine and Versed were present shortly before the patients died and that, in his view, no competing cause explained the deaths. Wecht also disputed Karch’s position. He considered some detected levels very high and conducted a small experiment in which overdose samples were exposed to hot, humid conditions; he found no significant difference between those samples and refrigerated comparisons. The experiment was not definitive, independently vetted, or published, leaving it as one piece of evidence rather than a resolution of the disagreement.

Wider Significance

Midazolam also appeared in reports about deaths at Touro and Specialty Hospital of New Orleans, where toxicology tests on some recovered bodies found high levels of the same combination of morphine and midazolam. The recurrence widened the inquiry beyond Memorial, but did not make the circumstances at the different facilities identical. Each patient’s records, condition, treatment, and evacuation circumstances remained relevant to interpreting a result.

The medication’s significance therefore rests on a chain of distinctions. In intensive care it could be used to sedate and ease distress, including before withdrawal of life support. In the Memorial investigation, its presence in postmortem tissue, its appearance alongside morphine, and the circumstances surrounding pharmacy supplies and patient care prompted questions about how and why it had been administered. Yet toxicology could not, without clinical and testimonial evidence, independently establish the exact dose, the effect on an individual patient, or a caregiver’s intent. The book keeps those questions in view: midazolam is at once a familiar tool of medical practice and a forensic trace whose meaning depends on evidence beyond the trace itself.